Jasper Therapeutics, Inc. (NASDAQ:JSPRW) Short Interest Update

Jasper Therapeutics, Inc. (NASDAQ:JSPRW) was the target of a significant drop in short interest in November. As of November 15th, there was short interest totalling 16,400 shares, a drop of 18.0% from the October 31st total of 20,000 shares. Based on an average daily volume of 5,000 shares, the short-interest ratio is presently 3.3 days.

Jasper Therapeutics Price Performance

NASDAQ:JSPRW traded up $0.02 during mid-day trading on Monday, reaching $0.22. 127 shares of the company’s stock were exchanged, compared to its average volume of 16,684. The business’s fifty day simple moving average is $0.21 and its two-hundred day simple moving average is $0.21. Jasper Therapeutics has a one year low of $0.04 and a one year high of $0.38.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.